Boston Scientific Narrowing Gap With J&J In European DES Market
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific's Taxus stent is on track to claim half of the European drug-eluting stent market from rival and first-mover Johnson & Johnson/Cordis over the next several months, the firm says